课题基金 / 基金详情

Sentinel lymph node tumor burden quantified non-invasively and non-radioactively with multi-tracer and multispectral optoacoustic imaging

Sentinel lymph node tumor burden quantified non-invasively and non-radioactively with multi-tracer and multispectral optoacoustic imaging
通过多示踪剂和多光谱光声成像对前哨淋巴结肿瘤负荷进行非侵入性和非放射性定量
批准号:
367623384
负责人:
Professor Dr. Joachim Klode
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2017
资助国家:
德国
项目状态:
已结题
起止时间:
2016-12-31 至 2020-12-31

项目摘要

项目成果

Professor Dr. Joachim Klode的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Melanoma skin cancer is an aggressive and deadly tumor. According to the World Health Organization, the incidence of melanoma is increasing faster than any other major cancer in the world. Melanoma is the fifth most common cancer in Germany, posing a substantial health and economic burden. Melanoma metastasizes early into regional lymph nodes, requiring sentinel lymph node (SLN) histological status for prognostication and determination of patient survival. Sentinel lymph node excision (SLNE) is therefore recommended in the current 2009 AJCC guidelines. Widely used for decades, SLNE with histological analysis has proved to be effective and reliable, but it does have drawbacks. The gold standard for targeted extirpation of the SLN is lymphoscintigraphy using 99m-technetium (99mTc), which invariably represents a radioactive burden for patients and (to a lesser degree) caregivers. Furthermore there is a worldwide shortage of technetium-99m. SLNE is further a very cost-intensive intervention with potential morbidity, not found to improve overall patient survival. As only a portion of the node is sampled for histology, the optimal mode of pathological sectioning remains controversial and could in part explain the high false-negative rate of SLNE reported (9-44%). These drawbacks suggest that alternative strategies for SLN identification and diagnosis should be explored.In the proposed grant we will develop a new imaging approach which has the potential to quantify amelanotic and melanotic cancer cell burden in melanoma draining lymph nodes with high sensitivity and specificity. In the end we will have developed the first and only cost effective, noninvasive and nonradioactive approach for detecting microscopic levels of cancer cells in tumor draining lymph nodes. In the future this approach could also be applied to other solid tumors such as breast cancer where the economic and medical impact would be far greater.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.ejca.2021.09.026
发表时间: 2021-11
期刊: European journal of cancer
影响因子: 8.4
作者: [Simon F. Merz;P. Jansen;Ricarda Ulankiewicz;L. Bornemann;T. Schimming;K. Griewank;Zülal Cibir;Andreas Kraus;I. Stoffels;T. Aspelmeier;S. Brandau;D. Schadendorf;E. Hadaschik;G. Ebel;M. Gunzer;J. Klode]
通讯作者: Simon F. Merz;P. Jansen;Ricarda Ulankiewicz;L. Bornemann;T. Schimming;K. Griewank;Zülal Cibir;Andreas Kraus;I. Stoffels;T. Aspelmeier;S. Brandau;D. Schadendorf;E. Hadaschik;G. Ebel;M. Gunzer;J. Klode
Randomized Clinical Trial Comparing Sentinel Lymph Node Excision (SLNE) with or without preoperative hybrid "single-photon emission computed tomography/computed tomography" (SPECT/CT) in Melanoma. (SNEPS-Trial)
  • 批准号:
    326107690
  • 项目类别:
    Clinical Trials
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Professor Dr. Joachim Klode
  • 依托单位:
海外基金